Achilles Therapeutics (NASDAQ: ACHL)
$1.1500
+0.0200 ( +2.68% ) 237.7K
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Market Data
Open
$1.1500
Previous close
$1.1300
Volume
237.7K
Market cap
$46.43M
Day range
$1.1100 - $1.1500
52 week range
$0.6300 - $1.7600
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Form 6-K | 3 | Dec 26, 2024 |
| 6-k | Form 6-K | 1 | Dec 02, 2024 |
| 6-k | Form 6-K | 5 | Nov 14, 2024 |
| 6-k | Form 6-K | 3 | Sep 19, 2024 |
| 6-k | Form 6-K | 69 | Aug 14, 2024 |
| 6-k | Form 6-K | 1 | Aug 05, 2024 |
| 6-k | Form 6-K | 1 | Jun 27, 2024 |
| 6-k | Form 6-K | 11 | May 24, 2024 |
| 6-k | Form 6-K | 3 | May 17, 2024 |
| 6-k | Form 6-K | 5 | May 08, 2024 |